Summary of China Life Insurance Conference Call Company Overview - **Company**: China Life Insurance - **Industry**: Insurance Key Points and Arguments 2026 Performance Expectations - The 2026 "开门红" (New Year sales) performance exceeded expectations, with rapid growth in the bancassurance channel outpacing individual insurance sales. The proportion of participating products, especially pension annuities, has significantly increased, accounting for approximately 60-70% of sales. The growth rate of 10-year premium payment policies surpassed that of first-year new policies, indicating an improvement in business structure. The value rate has improved due to a reduction in the preset interest rate from the previous year [2][5][11]. Strategic Focus on Bancassurance - The bancassurance channel has been elevated to a strategic development channel, with plans to expand network coverage and enhance existing network productivity. The company aims to strengthen partnerships with major banks and explore potential collaborations with joint-stock banks, primarily focusing on selling participating insurance products [2][8]. Product Management and Profitability - The company maintains strict duration management for participating and traditional insurance products. The effective duration gap has narrowed from two years last year to one year, reflecting a further reduction in overall effective duration. The shift towards participating products is seen as a correct long-term strategy, with regulatory support expected for floating yield products in the future [2][7][10]. New Product Launches - China Life is closely monitoring new regulations for participating health insurance and plans to launch related products in 2026, which is expected to drive sales growth. The anticipated profit margin for participating critical illness insurance is projected to be around 30-40%, with interest spread remaining the primary source of profit, accounting for approximately 80% [2][12][13][14]. Interest Rate and Investment Strategy - It is expected that interest rates will remain low and fluctuate in 2026, with a potential breakthrough in term spreads. The company will continue a neutral and flexible allocation strategy, focusing on high-grade credit bonds while controlling duration. The equity market is anticipated to be volatile, with a focus on cyclical recovery sectors and technology growth sectors, while also accumulating high-dividend stocks [4][19][24]. Regulatory Impact and Taxation - The company has transitioned to new accounting standards and has made arrangements for deferred tax liabilities considering the differences between old and new standards. The impact of these changes on profits is deemed manageable [3][18]. Dividend Policy and Financial Health - The company’s dividend policy is expected to remain robust, with a projected 19% year-on-year increase in mid-year dividends for 2026. The overall profit growth is anticipated to be strong, with no immediate plans for debt issuance due to sufficient capital adequacy and solvency [26]. Market Position and Competitor Analysis - The company views the recent acquisition of insurance stocks by Ping An as a recognition of operational development. Holding peer insurance stocks as part of a high-dividend strategy is common practice, and China Life holds shares in Ping An, reflecting confidence in industry prospects [27]. Additional Important Insights - The company’s demonstration interest rates are positioned at an industry average of 3.0% to 3.5%, aimed at setting reasonable customer expectations without misleading them. The final returns depend on long-term investment capabilities and actual performance levels [15][18]. - The company is considering different guarantee levels for future product designs to enhance customer appeal and investment strategies [16][17]. This summary encapsulates the key insights from the conference call, highlighting the strategic direction, product management, and market positioning of China Life Insurance.

来源：上海证券报·中国证券网 新华保险10月30日在上证e互动平台回答投资者提问表示，这为近年来相对低迷的疾病险业务发展带来 了重要发展机遇，是健康保险领域供给侧改革的重要举措之一。新政出台后，公司高度重视，正研究各 项落地措施，启动分红重疾险的研发工作。 上证报中国证券网讯（记者 韩宋辉）金融监管总局近日出台《关于推动健康保险高质量发展的指导意 见》，支持监管评级良好的保险公司开展分红型长期健康保险业务。 ...